Review Article
Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma
Table 2
Results of prospective, phase II trials evaluating allogeneic hematopoietic cell transplantation after reduced intensity conditioning.
| | Author (Year) | Number of patients | Age (range) | Conditioning regimen | TRM | EFS/PFS | OS | Comments |
| | Khouri et al. [48, 52] (2008 and 2012) | 47 | 53
(33–68) | FCR +/− ATG | 15%
(5 years) | 72%
(11 years) | 78%
(11 years) | Grades 2–4 acute GVHD in 11%. All had chemosensitive disease. High-dose rituximab (1000 mg/m2) used. |
| | Thomson et al. [49] (2010) | 82 | 45
(26–65) | FMC | 15%
(4 years) | 76%
(4 years) | 76%
(4 years) | Grades 2–4 acute GVHD in 13%. Included 26% with prior auto-HCT and 9% with refractory disease. |
| |
Piana et al. [50] (2010) | 37 | 50
(34–62) | FM | 35%* | 57%
(4 years) | 54%
(4 years) | Grades 2–4 acute GVHD in 47%. Included 46% with prior auto-HCT. |
| | Shea et al. [51] (2011) | 44
(16 had FL) | 53
(39–68) | FC | 9%
(3 years) | 75%
(3 years) | 81%
(3 years) | All were sibling donors and none had prior auto-HCT. |
|
|
Abbreviations: FL: follicular lymphoma; FCR: fludarabine, cyclophosphamide, rituximab; ATG: antithymocyte globulin; F: fludarabine, M: melphalan, C: campath; FC: fludarabine, cyclophosphamide; TRM: treatment-related mortality; EFS/PFS: event/progression-free survival; OS: overall survival; GVHD: graft versus host disease; auto-HCT: autologous hematopoietic cell transplantation. *TRM estimated from numbers in the publication.
|
